Nature Cancer September issue cover.

Series on Cancer Immunotherapy

Check out our Series on Cancer immunotherapy for Reviews, Perspectives and opinion pieces on the latest advances and challenges in clinical translation of promising discoveries in this field. 

Announcements

  • We are seeking a new Associate/Senior Editor to join our editorial team. This is a new position to support the growth of the journal and is open to our New York, Washington DC, Philadelphia, Berlin, London, Madrid, and Shanghai offices. Application deadline October 28th.

  • Image of an organoid

    Join us for a webcast entitled, “3D models in Cancer Research”, with Dr. Karuna Ganesh and Dr. Gordana Vunjak-Novakovic. Register free to join the presentations and the live Q&A. Presented by Springer Nature and Thermo Fisher Scientific. October 12, 2022 | 1:00 PM EDT

  • Nature Cancer pictorial

    View webcasts hosted by Nature Cancer editors, in which expert cancer researchers and clinicians discuss the most exciting advances and biggest challenges in their fields. Past events can be accessed on demand for free by registering your attendee details.

  • Nature Cancer Series Cover - image of medications in ingestible and injectable form.

    Nature Cancer presents a Series of commissioned Review and Perspective articles highlighting emerging concepts in cancer therapy, novel therapeutic approaches and the challenges in translating preclinical findings into clinical benefit, accompanied by a collection of relevant primary research and News and Comment articles published by Nature Cancer.

Nature Cancer is a Transformative Journal; authors can publish using the traditional publishing route OR via immediate gold Open Access.

Our Open Access option complies with funder and institutional requirements.

Advertisement

    • Increasing evidence links RNA methyltransferases to DNA damage repair. METTL16 is now shown to antagonize homologous recombination by preventing DNA-end resection via MRE11. Thus, METTL16 may represent a cancer vulnerability that can be used to identify patients able to benefit from combination therapies with DNA-damaging agents.

      • Marcelo Perez-Pepe
      • Claudio R. Alarcón
      News & Views
    • Therapeutic resistance in prostate cancer can be driven by lineage plasticity, but the mechanisms behind this are unclear, and therapies to prevent or reverse the process are nonexistent. A new study reveals the JAK/STAT signaling axis as a driver of lineage plasticity with tremendous therapeutic potential.

      • Nicholas J. Brady
      • Christopher E. Barbieri
      News & Views
    • The identification of tumor-reactive T cells using phenotypic markers is now well established in treatment-naive tumors. It is unclear, however, whether these markers can also be useful after immune checkpoint blockade (ICB). A new study finds that CXCL13 expression robustly identifies tumor-reactive T cells before and after ICB and is associated with treatment response.

      • Paulien Kaptein
      • Daniela S. Thommen
      News & Views
    • Mesenchymal-like and pluripotency-like programs coordinate the dissemination and long-lived dormancy of early breast cancer cells. The transcription factor ZFP281 controls these programs, preventing the acquisition of an epithelial-like proliferative phenotype and serving as a previously unrecognized barrier to metastasis.

      Research Briefing
  • Deeper insights into context-specific cancer cell states and the mechanisms that underlie the phenotypic plasticity of different cancer types are key to tackling tumor formation, therapy resistance and recurrence after therapy.

    Editorial
  • Malignant pleural mesothelioma is a challenging disease with few approved treatments. Rapidly expanding insights into the pathogenesis of this cancer and clinical trials are now suggesting a variety of targeted and immune-oncology agents with the potential to address unmet clinical needs.

    • Dean A. Fennell
    • Aleksandra Bzura
    Clinical Outlook
  • The true impact of a paper, a researcher’s work or a journal’s value cannot be captured by any one metric but requires a more nuanced approach that combines quantitative and qualitative measures.

    Editorial
  • The US Supreme Court’s ruling to overturn Roe v. Wade will affect patients with cancer and cancer care providers across the United States. In this time of uncertainty, it is imperative to protect health rights and evidence-based care.

    Editorial
  • The advent of immunotherapy has revolutionized the cancer field, but it is not without its challenges. In this issue, we launch our Series on Cancer Immunotherapy presenting commissioned Reviews and opinion pieces on the latest advances and efforts to expand the palette of immunotherapies and their clinical translation.

    Editorial
  • As guidelines, therapies and literature on cancer variants expand, the lack of consensus variant interpretations impedes clinical applications. CIViC is a public-domain, crowd-sourced and adaptable knowledgebase of evidence for the clinical interpretation of variants in cancer, designed to reduce barriers to knowledge sharing and alleviate the variant-interpretation bottleneck.

    • Kilannin Krysiak
    • Arpad M. Danos
    • Malachi Griffith
    Comment
Image of different types of therapies, including pills and injectables, taken from the March 2021 issue cover of Nature Cancer.

Series on Cancer Therapy

Cancer therapy has advanced significantly in recent years, however, cancer remains a major health problem that requires further discovery and innovation to improve outcomes and quality of life for patients.
Series

Advertisement